Moleculin Biotech, Inc. 8-K

What Happened

• Moleculin Biotech, Inc. filed an 8-K on June 30, 2026, disclosing two items: a Regulation FD disclosure attaching an investor presentation (Exhibit 99.1) and an other-event update that warrants to purchase 1,361,500 shares were exercised for gross proceeds of approximately $2.7 million. The warrant exercises occurred after the company’s Form 10-Q filing for the period ended March 31, 2026 (filed May 14, 2026). As of June 29, 2026, Moleculin had 7,065,000 shares of common stock outstanding.

Key Details

• Filed: Form 8-K dated June 30, 2026 (Regulation FD disclosure and Other Events).
• Warrants exercised: 1,361,500 warrants converted, generating roughly $2.7 million in gross proceeds.
• Shares outstanding: 7,065,000 common shares as of June 29, 2026.
• Investor materials: Company posted an investor presentation dated June 2026 as Exhibit 99.1.

Why It Matters

• The exercised warrants provided the company with near-term cash of about $2.7M, which can affect short-term funding and operations.
• The conversion increased the share count to 7,065,000, a dilution factor investors should consider when evaluating per-share metrics (e.g., earnings per share, ownership percentages).
• Posting an updated investor presentation under Regulation FD makes corporate updates publicly available and may include strategic or financial details investors will want to review.